{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:54:55Z","timestamp":1760298895422},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2014,5,1]],"date-time":"2014-05-01T00:00:00Z","timestamp":1398902400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2014,5]]},"DOI":"10.1002\/jps.23916","type":"journal-article","created":{"date-parts":[[2014,3,6]],"date-time":"2014-03-06T19:48:41Z","timestamp":1394135321000},"page":"1548-1556","source":"Crossref","is-referenced-by-count":11,"title":["Pharmacokinetic Interactions Between the Orexin Receptor Antagonist Almorexant and the CYP3A4 Inhibitors Ketoconazole and Diltiazem"],"prefix":"10.1016","volume":"103","author":[{"given":"Jasper","family":"Dingemanse","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans Gabriel","family":"Cruz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martine","family":"Gehin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Petra","family":"Hoever","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1002\/jps.23916_bb0010","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1517\/13543784.16.11.1785","article-title":"The hypocretin\/orexin receptor: Therapeutic prospective in sleep disorders","volume":"16","author":"Nishino","year":"2007","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1002\/jps.23916_bb0015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1111\/bph.12261","article-title":"Discovery and development of orexin receptor antagonists as therapeutics for insomnia","volume":"171","author":"Winrow","year":"2013","journal-title":"Br J Pharmacol"},{"key":"10.1002\/jps.23916_bb0020","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1073\/pnas.95.1.322","article-title":"The hypocretins: Hypothalamus-specific peptides with neuroexcitatory activity","volume":"95","author":"de Lecea","year":"1998","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1002\/jps.23916_bb0025","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/S0092-8674(00)80949-6","article-title":"Orexins and orexin receptors: A family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior","volume":"92","author":"Sakurai","year":"1998","journal-title":"Cell"},{"key":"10.1002\/jps.23916_bb0030","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1111\/j.1749-6632.2010.05513.x","article-title":"The orexin system: Roles in sleep\/wake regulation","volume":"1200","author":"Sakurai","year":"2010","journal-title":"Ann N Y Acad Sci"},{"key":"10.1002\/jps.23916_bb0035","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1007\/s11910-010-0101-y","article-title":"Hypocretins in the control of sleep and wakefulness","volume":"10","author":"Bonnavion","year":"2010","journal-title":"Curr Neurol Neurosci Rep"},{"key":"10.1002\/jps.23916_bb0040","first-page":"29","article-title":"The regulation of sleep and wakefulness by the hypothalamic neuropeptide orexin\/hypocretin","volume":"75","author":"Inutsuka","year":"2013","journal-title":"Nagoya J Med Sci"},{"key":"10.1002\/jps.23916_bb0045","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1038\/nm1544","article-title":"Promotion of sleep by targeting the orexin system in rats, dogs and humans","volume":"13","author":"Brisbare-Roch","year":"2007","journal-title":"Nat Med"},{"key":"10.1002\/jps.23916_bb0050","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1038\/clpt.2010.19","article-title":"Orexin receptor antagonism, a new sleep-promoting paradigm: An ascending single-dose study with almorexant","volume":"87","author":"Hoever","year":"2010","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.23916_bb0055","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/clpt.2011.370","article-title":"Orexin receptor antagonism, a new sleep-enabling paradigm: A proof-of-concept clinical trial","volume":"91","author":"Hoever","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"10.1002\/jps.23916_bb0060","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1124\/dmd.112.050120","article-title":"Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans","volume":"41","author":"Dingemanse","year":"2013","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.23916_bb0065","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug\u2013drug interaction studies: A pharmaceutical research and manufacturers of America (PhRMA) perspective","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1002\/jps.23916_bb0070","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s00228-012-1470-8","article-title":"Almorexant effects on CYP3A4 activity studied by its simultaneous and time-separated administration with simvastatin and atorvastatin","volume":"69","author":"Hoch","year":"2013","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1002\/jps.23916_bb0075","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1177\/0091270008331133","article-title":"Effect of different durations of ketoconazole dosing on the single-dose pharmacokinetics of midazolam: Shortening the paradigm","volume":"49","author":"Stoch","year":"2009","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.23916_bb0080","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1177\/0091270010387141","article-title":"Effect of different durations and formulations of diltiazem on the single-dose pharmacokinetics\u00a0of midazolam: How long do we go?","volume":"51","author":"Friedman","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.23916_bb0085","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1128\/AAC.21.5.730","article-title":"Impairing effect of food on ketoconazole absorption","volume":"21","author":"M\u00e4nnist\u00f6","year":"1982","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1002\/jps.23916_bb0090","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1177\/0091270010377634","article-title":"Food effect and biocomparison of two formulations of the dual orexin receptor antagonist almorexant in healthy male subjects","volume":"51","author":"Hoch","year":"2011","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.23916_bb0095","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1159\/000335367","article-title":"Absolute oral bioavailability of almorexant, a dual orexin receptor antagonist, in healthy human subjects","volume":"89","author":"Hoch","year":"2012","journal-title":"Pharmacology"},{"key":"10.1002\/jps.23916_bb0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1517\/17425255.2012.639360","article-title":"Effect of posaconazole on the pharmacokinetics of simvastatin and midazolam in healthy volunteers","volume":"8","author":"Krishna","year":"2012","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1002\/jps.23916_bb0105","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1177\/0091270006294277","article-title":"Grapefruit-drug interactions: Can interactions with drugs be avoided?","volume":"46","author":"Mertens-Talcott","year":"2006","journal-title":"J Clin Pharmacol"},{"key":"10.1002\/jps.23916_bb0110","first-page":"280","article-title":"The grapefruit: An old wine in a new glass? Metabolic and cardiovascular perspectives","volume":"21","author":"Owira","year":"2010","journal-title":"Cardiovasc J Afr"},{"key":"10.1002\/jps.23916_bb0115","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1208\/s12248-009-9146-8","article-title":"Herb-drug interactions with St. John's wort (Hypericum perforatum): An update on clinical observations","volume":"11","author":"Borrelli","year":"2009","journal-title":"AAPS J"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915305918?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354915305918?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T01:59:14Z","timestamp":1538791154000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354915305918"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014,5]]}},"alternative-id":["S0022354915305918"],"URL":"https:\/\/doi.org\/10.1002\/jps.23916","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2014,5]]}}}